Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension

Podobne zapisy

• Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
  od: Frey, Reiner, i wsp.
  Wydane: (2009)
• Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
  od: Frey, Reiner, i wsp.
  Wydane: (2016)
• Cardio-renal protection of riociguat (BAY 63-2521) in low- and high-renin models of hypertension
  od: Kalk, Philipp, i wsp.
  Wydane: (2009)
• No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
  od: Frey, Reiner, i wsp.
  Wydane: (2011)
• Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality
  od: Becker, Corina, i wsp.
  Wydane: (2016)